Compared with normal tissues, whether ABCG2, TOX3, or WDR5 is up-regulated in clinical metastatic and drug-resistant tumor specimens, and shows a strong prognostic value for OS and DFS in drug-resistant CRC patients. This evidence concerns the gene TOX3 and neoplasm.